Bottom line compliance for biotechnology: Six secrets

Abstract

Biotechnology executives frequently short-shrift one of the key indicators of return on investment when negotiating pharmaceutical partnerships, support or licensing: a compliance and quality system. Given the increasingly tight financial markets biotechnology executives must operate within, can a good quality system be established for less than the cost of an average car?